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Abstract
Background: The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients
with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far
about the clinical impact of AQP4-Ab seropositivity.
Objective: To analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders
in Caucasians in a stratified fashion according to the patients’ AQP4-Ab serostatus.
Methods: Retrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3%).
Results: Seropositive patients were found to be predominantly female (p < 0.0003), to more often have signs of
co-existing autoimmunity (p < 0.00001), and to experience more severe clinical attacks. A visual acuity of ≤ 0.1
during acute optic neuritis (ON) attacks was more frequent among seropositives (p < 0.002). Similarly, motor
symptoms were more common in seropositive patients, the median Medical Research Council scale (MRC) grade
worse, and MRC grades ≤ 2 more frequent, in particular if patients met the 2006 revised criteria (p < 0.005, p <
0.006 and p < 0.01, respectively), the total spinal cord lesion load was higher (p < 0.006), and lesions ≥ 6 vertebral
segments as well as entire spinal cord involvement more frequent (p < 0.003 and p < 0.043). By contrast, bilateral
ON at onset was more common in seronegatives (p < 0.007), as was simultaneous ON and myelitis (p < 0.001);
accordingly, the time to diagnosis of NMO was shorter in the seronegative group (p < 0.029). The course of
disease was more often monophasic in seronegatives (p < 0.008). Seropositives and seronegatives did not differ
significantly with regard to age at onset, time to relapse, annualized relapse rates, outcome from relapse (complete,
partial, no recovery), annualized EDSS increase, mortality rate, supratentorial brain lesions, brainstem lesions, history
of carcinoma, frequency of preceding infections, oligoclonal bands, or CSF pleocytosis. Both the time to relapse
and the time to diagnosis was longer if the disease started with ON (p < 0.002 and p < 0.013). Motor symptoms or
tetraparesis at first myelitis and > 1 myelitis attacks in the first year were identified as possible predictors of a
worse outcome.
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Conclusion: This study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and
demonstrates a number of distinct disease characteristics in seropositive and seronegative patients.
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Background
Neuromyelitis optica (NMO) is a severely disabling
inflammatory disorder of the central nervous system
(CNS) of putative autoimmune aetiology that predomi-
nantly affects the optic nerves and spinal cord [1].
NMO is associated with serum antibodies to aquaporin-
4, the most abundant water channel in the CNS in up
to 80% of cases [2-7]. These antibodies (termed NMO-
IgG or AQP4-Ab) are thought to be directly involved in
the pathogenesis of the condition [8-16]. The clinical
spectrum of NMO as defined by Wingerchuk et al.
(2007) [17] comprises cases of simultaneous optic neuri-
tis (ON) and myelitis, cases of myelitis and ON, in
which the two index events do not develop simulta-
neously but successively, and limited or inaugural forms
such as single or recurrent events of longitudinally
extensive myelitis (LETM) or recurrent ON [17-21].
More rarely, patients may present with brain stem ence-
phalitis [22,23].
Similar to other autoimmune neurological diseases
such as myasthenia gravis, a subset of patients exists
who are seronegative. There are indications that seropo-
sitive and seronegative patients might differ with regard
to clinical presentation or prognosis [24,25]. However,
as AQP4-Ab were discovered only a few years ago,
many previous studies investigating the clinical and
paraclinical features associated with myelitis and optic
neuritis in patients with NMOSD either did not deter-
mine AQP4-Ab at all [1,26], or did not stratify patients
according to their AQP4-Ab serostatus [27,28], or were
based on relatively small patient numbers [24,25,28-34].
Moreover, some of these previous studies did not
include Caucasians [25,35] or investigated mixed non-
Caucasian/Caucasian cohorts [1,36]. Finally, many pre-
vious studies were monocentre investigations and thus
prone to potential selection bias.
In the present multicentre study, we aimed to analyse
the clinical and paraclinical features of NMOSD in Cau-
casians in a stratified fashion according to the patients’
AQP4-Ab serostatus.
Patients and methods
Clinical, MRI, and CSF features from all Caucasian
patients with NMOSD as defined by Wingerchuk et al.
(2007) [17] and known AQP4-Ab serostatus documen-
ted in the database of the German Neuromyelitis optica
Study Group (NEMOS; http://www.nemos-net.de) [37]
were analysed retrospectively. All patients were seen at
one of the 29 participating NEMOS centres, which
included neurological departments at 17 university hos-
pitals (Heidelberg, Berlin, Ludwig Maximilian University
of Munich, Düsseldorf, Würzburg, Regensburg, Tech-
nische Universität München, Ulm, Bochum, Frankfurt,
Tübingen, Hannover, Münster, Hamburg, Leipzig,
Rostock, Göttingen) and at 12 academic teaching hospi-
tals (Halle, Teupitz, Sigmaringen, Görlitz, Bayreuth,
Lübeck, Neubrandenburg, Alzey, Wiesbaden, Dortmund,
Stralsund, Plauen) with adjacent specialised outpatient
clinics for neuroinflammatory disorders. Case ascertain-
ment was performed between August 2009 and August
2011 by an expert panel of NEMOS members. The
study was approved by the Ethics Committee of the
Charité - University Medicine, Berlin, and the University
of Düsseldorf, Germany, and data analysis was per-
formed in an anonymized fashion according to the Ger-
man data protection law. The Mann Whitney U test
was used to test for significant differences between con-
tinuous variables and Fisher’s exact test (2-tailed) to
compare proportions. All tests should be understood as
constituting exploratory data analysis, such that no
adjustments for multiple testing have been made. Data
were analysed using Microsoft Excel 2003 and GraphPad
Prism 4.
At the time of analysis the database contained retro-
spective data from 175 Caucasian patients with NMOSD
as defined by Wingerchuk et al. (2007) [17] and known
AQP4-Ab serostatus. 119 patients had a history of both
ON and myelitis and met Wingerchuk’s 2006 revised
criteria [36] (seropositive in 77.3%), 49 had a history of
isolated LETM as defined by clinical myelitis and MRI
lesions extending over three or more vertebral segments
(seropositive in 81.6%), 7 had a history of recurrent ON
(seropositive in 71.4%). AQP4-Ab was determined in a
cell based assay in 55.4% [38], in a FACS based assay in
22.3% [6], in a radioimmunoprecipitation assay in 16%
[7], in a fluorescence immunoprecipitation assay in 3.4%
[4], and in an indirect immunofluorescence assay in
1.7% [2,3]. The median disease duration at last follow-
up was 57.5 months (range, 0-390) and did not differ
significantly between seropositives (60 months; range, 0-
390) and seronegatives (51 months; range, 0-290). 89%
had been treated with immunosuppressive or
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immunomodulatory agents at least once, with no signifi-
cant difference between seropositive and seronegative
patients (p = 0.133; Fisher exact test, 2-tailed); treat-
ments included interferon beta (20.6%), azathioprine
(45.1%), rituximab (32.6%), mitoxantrone (21.1%), oral
steroids (18.9%), cyclophosphamide (12.6%), intravenous
immunoglobulins (6.9%), mycophenolate mofetil (4%),
methotrexate (4%), and natalizumab (2.9%). If only
immunosuppressive drugs are considered, the propor-
tion of treated patients was higher in the seropositive
group (83% vs 65%; p = 0.015).
Results
Demographic data
The female to male ratio was 6:1 (N = 175) in the total
cohort and was significantly higher among seropositive
patients compared to seronegative patients (Table 1).
83.3% of the female but only 48% of the male patients
were seropositive. The median age at onset was 39 years
(range, 10-81) (Table 1). 24/175 patients (13.7%) were
older than 60 years at disease onset, and 9 of these were
older than 70 years.
Disease onset
Among patients with a history of both ON and myelitis,
disease started with isolated ON in 68/117 cases (58.1%),
with isolated myelitis in 29 (24.8%), with simultaneous
myelitis and ON in 15 (12.8%; bilateral ON in 6), and
with brain stem encephalitis without concomitant myeli-
tis or ON in 5 (4.3%). Simultaneous myelitis and ON at
onset was more common among seronegative patients
(Table 2). In those of them in whom the disease started
with ON (with or without concomitant myelitis), ON was
bilateral in 21.5% (17/79). ON was more frequently bilat-
eral at onset in seronegative patients (Table 2).
Disease course
The disease was relapsing at last follow-up in 156/175
(89.1%) patients and monophasic in 19 (ratio of
monophasic to relapsing, 1:8.21). A monophasic course
was more common among seronegative patients (Table
3) and, accordingly, also more frequent in patients in
whom the disease started with simultaneous myelitis
and ON (ratio, 1:2) compared to those in whom the dis-
ease started with either myelitis or ON (1:10.43) (p <
0.014).
Time to diagnosis and time to relapse
Among patients with a history of both ON and myelitis,
the correct diagnosis of NMO was made by the treating
physicians after a median of 37.5 months (range, 0-390;
Table 4). In 31/73 cases (42.5%) with available data,
patients were misdiagnosed with multiple sclerosis (MS)
by the initially treating physicians, mostly prior to the
availability of NMO-IgG/AQP4-Ab testing (83.9%). A
wrong initial diagnosis of MS became less common
once NMO-IgG/AQP4-Ab testing became commercially
available in 2005 (20% vs 54.2% before 2005) (p <
0.007). Of all patients who were initially falsely diag-
nosed with MS, 52.6% were treated with interferon beta
(IFN-beta) at least once in the course of disease com-
pared to 20.6% in the total cohort (p < 0.001); the fre-
quency of IFN-beta treatment was lowest in those
patients with a correct initial diagnosis (12.5%). Diag-
noses other than MS, LETM, or ON were initially sus-
pected in 11 cases, including among others acute
disseminated encephalomyelitis, connective tissue disor-
ders, and syringomyelia.
The correct diagnosis was made earlier if the disease
started with myelitis than if it started with ON (Table
4); this is partly explained by a longer median interval
between first ON and first myelitis than between first
myelitis and first ON (Table 5). In line with the finding
that NMO started more frequently with simultaneous
myelitis and ON in the seronegative group, the median
time to correct diagnosis was shorter among seronega-
tive patients (Table 4). The median number of ON and
myelitis attacks until the diagnosis of NMO was made
Table 1 Comparison of demographic features according to the patients’ AQP4-Ab serostatus.
Seropositive Seronegative p-level
Sex ratio (male:female)
All patients 1:10.4; N = 137 1:1.9; N = 38 p < 0.0003‡
Patients meeting Wingerchuk’s 2006
criteria
1:9.2; N = 92 1:2; N = 27 p < 0.006‡
Age at onset (median, range; N)
All patients 40 (10-81; N = 137) 38.5 (14-67; N = 38) n.s.§
Patients meeting Wingerchuk’s 2006
criteria
36 (10-79; N = 92) 37 (14-63; N = 27) n.s.§
Cases of death, attack-related 5/137 (3.6%)° 0/38 (0%) n.s.‡
°See results section for causes of death. Four additional patients died from non-attack related causes: One developed sepsis following plasma exchange; another
patient with a history of autonomic dysfunction with bradycardia and recent femoral vein thrombosis died from cardiovascular failure 3 days after the second
infusion with rituximab [80]; one patient died from voluntary refusal of nutrition and hydration after a severe attack of cervical myelitis that had left her
tetraplegic; and one died from an accident. ‡Fisher’s exact test (2-tailed). §Mann Whitney U test. N = number of patients; n.s. = not significant.
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Table 2 Symptoms at disease onset.
Seropositive Seronegative p-level
ON at onset
Total cohort 61/135 (45.2%) 14/38 (36.8%) n.s.‡
Patients meeting Wingerchuk’s 2006
criteria
56/90 (62.2%) 12/27 (44.4%) n.s.‡
MY at onset
Total cohort 64/135 (47.4%) 14/38 (36.8%) n.s.‡
Patients meeting Wingerchuk’s 2006
criteria
24/90 (26.7%) 5/27 (18.5%) n.s.‡
BSTE at onset
Total cohort 4/135 (3%) 1/38 (2.6%) n.s.‡
Patients meeting Wingerchuk’s 2006
criteria
4/90 (4.4%) 1/27 (3.7%) n.s.‡
Simultaneous MY and ON at onset
Total cohort 6/135 (4.4%) 9/38 (23.7%) p < 0.001‡
Patients meeting Wingerchuk’s 2006
criteria
6/90 (6.7%) 9/27 (33.3%) p < 0.013‡
Bilateral ON at onset
All patients with a history of ON 9/63 (14.3%) 9/22 (40.9%) p < 0.015‡
Patients meeting Wingerchuk’s 2006
criteria
9/59 (15.3%) 8/20 (40%) p < 0.029‡
Data are not available for 2/175 patients. ‡Fisher’s exact test (2-tailed). BSTE = brain stem encephalitis; MY = myelitis; n.s. = not significant; ON = optic neuritis.
Table 3 Comparison of clinical features according the patients’ AQP4-Ab serostatus.
Seropositive Seronegative p-level
Relapsing course
Total cohort 127/137 (92.7%) 29/38 (76.3%) p < 0.008‡
Patients meeting Wingerchuk’s 2006
criteria
92/92 (100%) 22/27 (81.5%) p < 0.0005‡
Relapse ratio, ON/MY* 0.85; N = 86 1; N = 25 n.s.§
Signs of-existing autoimmunity
Total cohort 76/130 (58.5%) 3/35 (8.6%) p < 0.00001‡
Patients meeting Wingerchuk’s 2006
Criteria
48/86 (55.8%) 3/25 (12%) P < 0.00009‡
Co-existing autoimmune disorders† 31/130 (23.8%) 2/35 (5.7%) p < 0.017‡
Co-existing auto-antibodies only†† 45/97(46.4%) 1/30 (3.3%) p < 0.00001‡
CSF-restricted OCB at first LP
All patients 30/110 (27.9%) 12/34 (35.3%) n.s.‡
Patients meeting Wingerchuk’s 2006
criteria
19/74 (25.7%) 10/26 (38.5%) n.s.‡
Median CSF white cell count at first LP
All patients 7 (0-750; N = 106) 7.5 (0-220; N = 30) n.s.§
Patients meeting Wingerchuk’s 2006
Criteria
7.5 (0-750; N = 68) 9 (1-220; N = 23) n.s.§
Preceding infections at least once# 27/92 (29.3%) 5/28 (17.9%) n.s.‡
Time to diagnosis of NMO (months) 11 (0-255; N = 29) p < 0.029§
*Only patients with a history of both ON and MY are considered (all meeting Wingerchuk’s 2006 criteria). † Diagnoses included autoimmune thyroiditis (N = 10),
systemic lupus erythematosus (8), acetylcholine receptor-antibody positive myasthenia gravis (4) [74], cutaneous lupus erythematosus, Sjögren’s syndrome, mixed
connective tissue disorder, anti-phospholipid antibody syndrome, celiac disease, psoriasis, bullous pemphigoid, pyoderma gangrenosum, vitiligo, atopic
dermatitis, sarcoidosis, HLAB27 positive ankylosing spondylitis with sacroileitis, heparin-induced thrombocytopenia, and rheumatoid arthritis. ††In the absence of
an established autoimmune disorder; including anti-nuclear antibodies (counted only if ≥ 1:240), antibodies to double stranded DNA, antibodies to single
stranded DNA, anti-histone antibodies, anti-centromere antibodies, anti-Scl70 antibodies, anti-SS/A antibodies, anti-SS/B antibodies, anti-phospholipid antibodies,
MPO-specific perinuclear antineutrophil cytoplasmic antibodies (pANCA), lactoferrin-specific pANCA, pANCA of unknown specificity, thyroid peroxidase antibodies,
anti-mitochondrial antibodies, anti-smooth muscle antibodies, and rheumatoid factor. #Preceding the first attack or preceding relapse at least once. ‡Fisher’s exact
test (2-tailed). §Mann Whitney U test. CSF = cerebrospinal fluid; LP = lumbar puncture; MY = myelitis; N = number of patients (not all data were available from all
patients); n.s. = not significant; OCB = oligoclonal bands; ON = optic neuritis; WCC = white cell count.
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was 1.0 (range, 1-5) and 1.0 (range, 1-8) attacks, respec-
tively. Thus, the diagnosis was not always delayed due
to wrong differential diagnostic considerations (e.g. in 4
cases initially diagnosed as MS, brain MRI was always
normal and oligoclonal bands never positive), but in
some patients the latency between the first ON attack
and the first myelitis attack (up to 349 months) or vice
versa (up to 217 months) was extraordinarily long.
Accordingly, in some patients a multitude of ON attacks
occurred before the first myelitis took place (up to 8
events) or vice versa (up to 4 myelitis events).
In the total cohort, the median time between first and
second event (irrespective of whether it was myelitis,
ON, a combination of both, or brain stem encephalitis)
was 8.5 months (Table 5). This interval did not differ
significantly between seropositive and seronegative
patients, but was significantly longer if the first event
was ON than if it was myelitis. Similarly, the median
latency between the first ON and the second ON was
longer than the median latency between the first and
the second myelitis. See Table 5 for details.
The difference was even more significant (p < 0.0002),
if patients with isolated ON at onset were compared to
all patients with symptoms other than isolated ON at
onset (i.e. myelitis [6 months (1-216; N = 61], or simul-
taneous myelitis and ON [median, 3.5 months; range, 1-
9; N = 10], or isolated brain stem symptoms [median, 5
months; range, 2-20; N = 4]).
Relapse frequency
The median number of documented relapses per patient
was 5 (range, 1-29). The ON to myelitis ratio was 0.9
among patients with NMO. Among all patients with a
history of myelitis and disease duration of > 12 months,
the median annual rate of myelitis attacks was 0.53
(range, 0.03-3.21). Among all patients with a history of
ON and disease duration of > 12 months, a median of
0.38 (range, 0.04-3) ON attacks per year had occurred
until the time of last follow-up. No significant difference
regarding the annual myelitis relapse, the annual ON
relapse rate, or the ON to myelitis ratio was found
between seropositive and seronegative patients (see
Table 3, 6 and 7). In 44/104 (42.3%) patients with
NMO, myelitis and ON occurred simultaneously at least
once; in another 32/60 (53.3%) the latency between
myelitis and ON (or vice versa) was as short as 1-3
months at least once.
Accrual of disability over time
In patients with a disease duration of ≥12 months, the
median annualized expanded disability status scale
(EDSS) increase was 0.65 (range, 0-4.29) based on the
presumption that the EDSS was 0 prior to disease onset.
Importantly, the annualized EDSS progression index did
not differ significantly between seropositive and serone-
gative patients, neither in the total cohort nor among
those patients who met Wingerchuk’s 2006 criteria.
Table 4 Time and number of attacks until the diagnosis of NMO was made by the treating physicians.
Time (median, range, N) p-level
All patients 37.5 months (0-390; 112)
ON at onset
MY at onset
55 months (0-390; 66)
16 months (0-255; 29)
P < 0.013§
Isolated ON or MY at onset
Simultaneous ON + MY at onset
49 months (0-390; 94)
1 month (0-18; 13)
P < 0.000001§
Seropositives
Seronegatives
45 months (0-390; 88)
11 months (0-255; 24)
P < 0.029§
Number of attacks (median, range, N)
ON attacks
MY attacks
1.0 (1-8; 118)
1.0 (1-5; 109)
n.s.§
§Mann Whitney U test. MY = myelitis; N = number of patients (not all data were available from all patients); n.s. = not significant; ON = optic neuritis.
Table 5 Time to relapse if disease started either with ON
or MY.
Time (median, range, N) p-level
1st ® 2nd attack†
All patients 8.5 months (1-216; N = 138) n.a.
Patients meeting
Wingerchuk’s 2006
criteria
9 months (1-216; N = 97) n.a.
Seropositives 9 months (1-201; N = 113) n.s.
Seronegatives 5 months (1-216; N = 25)
ON at onset 17 months (1-208; N = 67) p < 0.002§
MY at onset 6 months (1-216; N = 61)
MY+ON at onset 3.5 months (1-8; N = 10)
Brainstem
encephalitis at
onset
5 months (2-20; N = 4)
1st ON ® 2nd ON 24 months (1-381; 79) p < 0.0001§
1st MY ® 2nd MY 7 months (0-296; 121)
1st ON ® 1st MY 14 months (0-349; 85) p < 0.0005§
1st MY ® 1st ON 3 months (0-217; 41)
†Irrespective of whether the first event was ON or MY or simultaneous ON
and MY. §Mann Whitney U test. N = number of patients (not all data were
available from all patients); n.a. = not applicable; n.s. = not significant.
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Table 6 Optic neuritis, comparison of clinical features according to the patient’s AQP4-Ab serostatus.
Seropositive Seronegative p-level
Annualized ON relapse rate†
All patients with a history of ON 0.38 (0.04-2.25; N = 83) 0.36 (0.08-3; N = 21) n.s.§
Patients meeting Wingerchuk’s 2006
criteria
0.37 (0.04-2.25; N = 80) 0.25 (0.08-3; N = 19) n.s.§
Bilateral ON ever
All patients with a history of ON 25/92 (27.2%) 15/29 (51.7%) p < 0.023‡
Patients meeting Wingerchuk’s 2006
criteria
23/87 (26.4%) 14/27 (51.9%) p < 0.019‡
Bilateral ON at first ON attack*
All patients with a history of ON 12/85 (14.1%) 11/28 (39.3%) p < 0.007‡
Patients meeting Wingerchuk’s 2006
criteria
12/81 (14.8%) 10/26 (38.5%) p < 0.023‡
ON attacks with VA ≤ 0.1
All patients with a history of ON 83/123 (67.5%) 13/35 (37.1%) p < 0.002‡
Patients meeting Wingerchuk’s 2006
Criteria
74/112 (66.1%) 12/33 (36.4%) p < 0.005‡
Attacks with complete recovery
All patients with a history of ON 68/205 (33.2%) 15/51 (29.4%) n.s.‡
Patients meeting Wingerchuk’s 2006
Criteria
64/190 (33.7%) 13/42 (31%) n.s.‡
†Only patients with a disease duration > = 12 months were considered. *Irrespective of whether at disease onset or not. ‡Fisher’s exact test (2-tailed). §Mann
Whitney U test. ON = optic neuritis; N = number of patients (not all data were available from all patients); n.s. = not significant; VA = visual acuity.
Table 7 Myelitis, comparison of clinical features according to the patients’ AQP4-Ab serostatus.
Seropositive Seronegative p-level
Annualized myelitis attack rate†
All patients with a history of myelitis 0.6 (0.03-3.21; N = 108) 0.47 (0.04-2.88; N = 27) n.s.§
Patients meeting Wingerchuk’s 2006
Criteria
0.51 (0.03-2.73; N = 81) 0.39 (0.09-2.88; N = 20) n.s.§
Motor symptoms, first myelitis§
All patients with a history of myelitis 78/120 (65%) 22/35 (62.9%) n.s.‡
Patients meeting Wingerchuk’s 2006
Criteria
53/81 (65.4%) 17/27 (63%) n.s.‡
Motor symptoms, all attacks§
All patients with a history of myelitis 293/409 (71.6%) 54/91 (59.3%) p < 0.024‡
Patients meeting Wingerchuk’s 2006
Criteria
226/304 (74.3%) 42/74 (56.8%) p < 0.005‡
MRC grade during motor attack*
All patients with a history of myelitis 2 (0-5; N = 82) 3 (0-5; N = 24) p < 0.013§
Patients meeting Wingerchuk’s 2006
Criteria
2 (0-4.5; N = 55) 3.5 (0-5; N = 18) p < 0.006§
Motor attacks with MRC ≤ 2
All patients with a history of myelitis 88/159 (55.3%) 16/48 (33.3%) p < 0.009‡
Patients meeting Wingerchuk’s 2006
Criteria
71/119 (59.7%) 11/33 (33.3%) p < 0.01‡
Attacks with complete recovery
All patients with a history of myelitis 55/298 (18.5%) 7/61 (11.5%) n.s.‡
Patients meeting Wingerchuk’s 2006
Criteria
36/223 (16.1%) 6/49 (12.2%) n.s.‡
†Only patients with a disease duration > = 12 months were considered. *Median (range), calculated based on the patients’ individual median MRC grades during
all documented motor attacks. ‡ Fisher’s exact test (2-tailed). §Mann Whitney U test. §Based on 500 myelitis attacks with either (sensori)motor or sensory
symptoms; 3 further documented attacks were only associated with other symptoms such as bladder/bowel dysfunction or spasticity and were therefore not
included in the analysis. MRC = Medical Research Council; MY = myelitis; N = number of patients (not all data were available from all patients); n.s. = not
significant.
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Also, no difference was found if the analysis was
restricted to patients with a disease duration of ≥ 24, 36,
48, 60, or 100 months. Among all patients with a history
of myelitis and long term follow-up (≥ 100 months),
16% (4/21) had a low EDSS progression index of < 0.2/
year.
At last follow-up (median disease duration, 58
months; range, 0-390) the median EDSS was 5 (range,
0-10; N = 165). If only patients with a disease duration
of 100 months or more are considered (N = 51), the
median EDSS at last follow-up was 6.5 (range, 1.5-10).
Although there was a slight trend towards higher EDSS
values in seropositive patients compared to seronegative
patients (5 vs 4), the difference did not reach statistical
significance.
Importantly, twenty-one patients (16 seropositive, 5
seronegative; p = n.s.) had an EDSS of 1.5 or less, i.e. no
disability, at the time of last follow-up; the median dis-
ease duration was 36 months (range, 5-102) in this
group. See Figures 1 and 2 for additional details.
Predictive value of early clinical events
In patients with myelitis (with or without concomitant
ON) and long term follow-up data (≥ 100 months), pure
sensory symptoms at onset or at first myelitis were asso-
ciated with a better EDSS outcome at last follow-up
compared to patients with motor symptoms at onset
(Table 8). Also, tetraparesis at first myelitis and more
than one myelitis attack in the first year were associated
with a worse EDSS long term outcome (Table 8). By
contrast, neither bilateral optic nerve involvement at
first ON (irrespective if at onset or not) nor brain stem
involvement (at any point in time) did predict the EDSS
long term outcome.
Mortality rate and time-to-death
At the end of the observation period, 9/175 (6%)
patients (all of which were seropositive) had died. In 5
of these cases the cause of death was classified as
“directly related to NMO” by the last treating physicians.
The exact causes of death in these patients included
dyspnoea (with or without subsequent pneumonia) and
cardiac arrest associated with disease relapse in three,
but were not available retrospectively in two. Disease
duration at the time of death was 6, 53, 116, 158, and
284 months, respectively. See Table 1 for further details.
Myelitis - clinical findings
Motor symptoms occurred during 347/503 (69%) attacks
(197 × paraparesis, 81 × tetraparesis, 31 × hemiparesis,
34 × monoparesis, 4 × Brown Sequard syndrome). The
median MRC grade of all documented myelitis attacks
with motor symptoms was 3 (range, 0-5). While severe
paresis (MRC grade ≤2) was recorded during 49.3% of
all relapses with motor symptoms (including MRC grade
0 in one or more limbs in 19.7%), paresis was mild
(MRC grade 4 or 5-) in 31%. Severe paresis was more
Figure 1 EDSS and disease duration at last follow-up grouped
according to EDSS landmarks. EDSS < 2: No disability; EDSS 2-3.5:
Disability but unrestricted walking range; EDSS 4-5.5: Restricted
walking range but no walking aid required; EDSS 6-6.5: Walking aid
required; 7-9.5: Essentially restricted to wheelchair or bed. In five
cases the cause of death was directly related to attack-related
neurological deterioration (EDSS 10). In those 4 cases in which the
cause of death was not directly caused by neurological
deterioration, the EDSS score obtained at the last examination prior
to death was used for analysis.
Figure 2 Recovery from myelitis and median EDSS scores in
patients with NMO according to Wingerchuk et al. (2006) [36]
or LETM grouped for disease duration. In line with the low rate
of complete recovery from myelitis (A), a median EDSS of 4,
indicating a restricted walking range, was notable already early in
the disease course (B).
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frequent in the seropositive group than in the seronega-
tive group (Table 7); accordingly, the median of all
patients’ individual median MRC grades was worse in
the seropositive group (Table 7). Exclusively sensory
symptoms were recorded during 153 myelitis attacks
(29.9%); dysaesthesia or pain were explicitly mentioned
in 46 cases. Pure sensory attacks were more common in
the seronegative group and, accordingly, motor symp-
toms more common in the seropositive group (Table 7).
13 patients developed dyspnoea at least once over the
course of disease (seropositive in 11; seronegative in 2).
Other symptoms included ataxia, bladder and bowel dis-
turbances, erectile dysfunction, and Lhermitte’s sign.
In those with available data in whom the disease
started with myelitis (with or without concomitant ON),
motor symptoms were among the presenting symptoms
in 55/83 (66.3%), with tetraparesis (with dyspnoe in 1
case) being present in 15 of them. The median MRC
grade in this group was 3 (range, 0-5; N = 37); 14 of
these patients (37.8%) presented at onset with severe
paresis as indicated by an MRC grade ≤ 2.
Myelitis - MRI findings
At first myelitis, MRI showed at least one spinal cord
lesion extending over 3 or more vertebral segments in
127/137 patients with available data (92.7%). The med-
ian extension was 6 segments (range, 1-21; N = 137)
with a non-significant trend towards longer lesions in
seropositives (Table 9). In 21 patients (18 seropositive),
a second lesion was detected (median extension, 2 seg-
ments; range, 1-8), and in 8 patients (all seropositive) an
additional third lesion (median, 1 segment; range, 1-3)
was present. In those patients with several lesions, the
median total number of segments involved was 8 (range,
2-21). The total lesion load at first MRI correlated with
the EDSS at last follow up in patients with a disease
duration > = 100 months (Figure 3). The spinal conus
was involved in at least 4 patients. 37 patients had
lesions in the cervical portion of the spinal cord, 27 in
the thoracic portion, and 44 in both the cervical and the
thoracic portions. Lesions involved the lumbar or sacral
spinal cord in addition to the cervical or thoracic por-
tions in only 15 patients.
If all 326 spinal MRIs are considered, the median
length of the longest lesion in each MRI was 5 segments
(range, 1-21) and was slightly longer in seropositive
patients than in seronegative patients (Table 9). 286
MRIs (87.7%) showed lesions that ranged over 3 or
more segments. In 68 MRIs, a second lesion was detect-
able (median, 2 segments; range, 1-8), and in 19 of them
a third lesion (median, 1 segments; range, 1-3); the med-
ian total spinal cord lesion load of all MRIs was higher
in the seropositive group (Table 9). Very long lesions
extending over 6 or more segments were more frequent
among seropositives, and entire spinal cord involvement
as defined by contiguous spinal cord lesions extending ≥
17 vertebral segments occurred only in seropositive
patients (Table 9).
Myelitis - outcome
Myelitis attacks were mainly treated with intravenous
methylprednisolone (378 attacks) and/or plasma
exchange (78 attacks). Other treatments included oral
prednisolone, IVIG, and rituximab. Complete remission
was reported in 62/359 (17.3%), partial remission in 248
(69.1%), and no remission in 49 (14%). The proportion
of attacks with only partial or no recovery was lowest at
the time of the first attack and increased with the num-
ber of subsequent attacks (first attack, 75.6%; second,
87%; third: 85.7%; fourth, 79.5%; fifth, 81.8%; sixth,
100%; seventh, 88.9%; eighth, 100%; ninth, 100%; tenth,
100%) (Figure 2). No significant difference regarding
attack outcome (complete, partial, or no recovery) was
found between seropositive and seronegative patients
(Table 9). In 12/14 (85.7%) of those cases with severe
paresis (MRC grade ≤ 2) at onset, no or only partial
remission was achieved.
Optic neuritis - clinical findings
During the first documented ON attack, visual acuity
was ≤ 0.1 on either the left or the right eye in 30/39
(76.9%) patients with available data. In total, results
Table 8 Clinical events in the early disease course and long-term outcome.
Early events in the disease course EDSS outcome in patients with long term follow-up (≥ 100 months)
(median, range; N)
p-level
Motor symptoms at first myelitis*
Sensory symptoms at first myelitis*
7 (1.5-10; 29)
5.25 (2-9; 16)
p < 0.04§
Motor symptoms at onset
Sensory symptoms at onset
8.25 (5.5-10; 8)
4 (2-6.5; 5)
p < 0.007§
Tetraparesis at first myelitis*
Motor symptoms other than tetraparesis at first myelitis*
8.25 (7-10; 8)
6 (1.5-10; 21)
p < 0.003§
> 1 myelitis attacks during the first year
1 myelitis attack during the first year
8 (2.5-10; 7)
5.5 (2-8.5; 11)
p < 0.035§
*Irrespective of whether at disease onset or not. EDSS = expanded disability status scale; N = number of patients. § Mann Whitney U test.
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from 158 eye examinations during acute ON were avail-
able for analysis. 96 examinations (60.8%) in 62 patients
showed a visual acuity of ≤ 0.1 in the affected eye(s),
which was more frequent among seropositive than
among seronegative patients (Table 6).
At the end of the observation period, both the right
and the left eye had been affected at least once (either
simultaneously or successively) over the course of dis-
ease in 64% (78/121) of patients with a history ON and
in 76.1% (35/46) of those with long term follow-up (≥
100 months); simultaneous affection of both eyes
occurred at least once in 33.1% and 32.6%, retrospec-
tively. If all documented ON attacks are considered, ON
was bilateral in 19.8% or 62/251 attacks.
ON - outcome
ON attacks were mainly treated with intravenous
methylprednisolone (N = 198) alone or in combination
with plasma exchange or immunoadsorption (N = 30).
Other treatments included oral prednisolone, IVIG, and
rituximab. Complete remission was reported in 83/256
ON attacks (32.4%), partial remission in 126 (49.2%),
and no remission in 47 (18.4%). No differences regard-
ing outcome were observed between seropositive (no or
only partial recovery in 66.8%) and seronegative patients
(70.6%; Table 6). Complete remission was rare already
at disease onset; in 22/29 patients (75.9%) no or only
partial remission was achieved.
Brain stem lesions
In 46/175 patients (26.3%), clinical and/or radiological
signs of brain stem involvement were recorded at least
once over the course of disease, with no significant dif-
ference between seropositive and seronegative cases
(Table 10). In 15 of these patients, all of whom were
positive for AQP4-Ab, brain stem lesions occurred inde-
pendently of spinal cord or cerebral symptoms at least
once. Attack-related hiccups and/or vomiting, indicating
involvement of the medulla oblongata, were noted in 14
patients (all seropositive) during acute relapse. Other
brain stem symptoms observed included dysphagia, ocu-
lomotor dysfunction (internuclear opthalmoplegia, abdu-
cens nerve palsy, and nystagmus), ptosis, laryngeal
spasm, and tonic brain stem attacks. Although the
medulla oblongata was the most common site of infra-
tentorial lesions, lesions were also detected in the pons,
Table 9 Myelitis, comparison of spinal cord MRI features according to the patients’ AQP4-Ab serostatus.
Seropositive Seronegative p-level
Median lesion length†, first MRI 6 (1-21; N = 104) 4.5 (2-12; N = 26) n.s.§
Median lesion length†, all MRIs 5 (1-21; N = 264) 4 (1-16; N = 47) p < 0.01§
SC lesions ≥ 3 vertebral segments, 1st MRI 134/142 (94.4%) 38/40 (95%)# n.s.‡
SC lesions ≥ 3 vertebral segments, all MRIs 240/274 (87.6%) 46/51 (90.2%)# n.s.‡
SC lesions ≥ 6 vertebral segments, 1st MRI 63/115 (54.8%) 10/28 (35.7%) n.s.‡
SC lesions ≥ 6 vertebral segments, all MRIs 131/264 (49.6%) 12/47 (25.5%) p < 0.003‡
Patients with entire SC involvement at least once 15/132 (11.4%) 0/36 (0%) p < 0.043‡
MRIs with more than one lesion 59/274 (21.5%) 9/51 (17.6%) n.s.‡
Total lesion load*, first MRI 6.5 (1-21; 104) 5 (2-12; 26) p < 0.022§
Total lesion load*, all MRIs 6 (1-21; 264) 5 (1-16; 47) p < 0.006§
Total lesion load > 6 segments*, first MRI 65/104 (62.5%) 11/26 (42.3%) n.s.‡
Total lesion load > 6 segments*, all MRIs 153/264 (58%) 17/47 (36.2%) p < 0.007‡
Values are given as median (range, number) or as proportions. †If more than one lesion was present in the same MRI, the longest lesion was counted. *Median
cumulative length of all lesions present in the same spinal cord MRI. #Note that all seronegative patients with NMO according to Wingerchuk 2006 or LETM had
lesions extending over 3 or more vertebral segments at least once per definitionem. ‡Fisher’s exact test (2-tailed). § Mann Whitney U test. MRI = magnetic
resonance imaging; N = number of patients (not all data were available from all patients); n.s. = not significant; SC = spinal cord.
Figure 3 Correlation between the total spinal cord lesion load
at first myelitis as measured by MRI and the EDSS at last
follow-up in patients with a disease duration of at least 100
months.
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cerebellar peduncles, mesencephalon, and diencephalon
(bithalamic in one seropositive patient) in some patients.
Overall, 69 attacks involving the brain stem were
documented.
Supratentorial brain lesions
The first available brain MRI showed supratentorial
brain lesions in 81/168 (48.2%) cases. Lesions were clas-
sified as “compatible with a diagnosis of MS” in 14/81
patients (17.5%) by the treating radiologists, and as
“non-MS specific” in the remaining cases, with no differ-
ence between seropositives and seronegatives (Table 10).
Considering not only the first but all MRIs available for
analysis, supratentorial lesions were detectable in 99/168
patients (58.6%) at least once and in 179/351 MRIs
(51%). While 29/178 (16.3%) were classified by the read-
ing radiologists as showing lesions “compatible with
MS”, 150 were classified as showing “non-MS specific”
brain lesions. Only 3 out of 57 patients (5.3%) who had
no supratentorial lesions at first examination, and 5 out
of 34 (14.7%) patients who had non-MS specific supra-
tentorial lesions developed lesions classified as “compati-
ble with the diagnosis of MS” later in the disease course;
AQP4-Ab were positive in all of these cases. In addition,
15 out of 57 patients (26.3%) who had a normal first
supratentorial brain MRI developed “non-MS-specific”
supratentorial lesions later on (seropositive in 12). In
the remaining cases, no follow-up brain MRI was
performed.
CSF findings
At first lumbar puncture (LP), cerebrospinal fluid
(CSF) restricted oligoclonal bands (OCBs) were present
in 42/144 patients (29.2%) with no significant differ-
ence between seropositives and seronegatives (Table
3). Follow-up results were available from 83 patients
(65 from initially OCB-negative patients and 18 from
initially OCB-positive patients). 10/65 patients that
were negative for OCBs at first LP (15.4%) developed
OCBs later, and 10/18 patients positive for OCBs at
first LP (55.6%), turned negative at follow-up. Conse-
quently, 52/144 (36.1%) patients were positive for
OCBs at least once. The intrathecal, polyspecific
humoral immune response to measles, rubella, and
varicella zoster (so called ‘MRZ reaction’) [39], a mar-
ker of classical MS, was tested in 18 patients (seroposi-
tive in 13) but was negative in all of them (7 of whom
have previously been reported in [40]).
CSF white cell numbers at first lumbar puncture were
rather low (median 7/μl; range, 0-750; N = 136). CSF
pleocytosis, as defined by a white cell count (WCC) > 5/
μl, was present at first LP in 95/146 patients (65.1%;
median, 18 cells/μl; range, 6-750). The frequency of
pleocytosis as well as the median WCC did not differ
between seropositive and seronegative patients (Table
3). CSF neutrophils were documented in 29 cases (med-
ian, 10% of all white cells; range, 1-93.33%; seropositive
in 25); however, cytological results were not available
from most patients.
Preceding infections
Attacks were reported to have occurred following acute
infection in 32 patients (Table 3). In 9 cases (one of
whom was previously reported [41], acute herpes virus
infection (herpes zoster in 5; herpes facialis in 1; “cuta-
neous herpes infection” in 1) preceded the first attack.
One patient was first diagnosed with active tuberculosis
of the lung at NMO onset. Other preceding events
included “common cold” and “feverish infection” (N =
10); sinusitis (2); otitis media (1); bronchitis (1); pneu-
monia (1); urinary tract infection (7; including urosepsis
in 1); and gastrointestinal infection (2).
Table 10 Frequency of supratentorial and infratentorial brain involvement.
Seropositive
(No of patients, %)
Seronegative
(No of patients, %)
p-level
Supratentorial brain lesions at first MRI
Total cohort 63/133 (47.4%)† 16/35 (45.7%)† n.s.‡
Patients meeting Wingerchuk’s 2006
criteria
38/89 (42.7%) 13/26 (50%) n.s.‡
Supratentorial brain lesions ever
Total cohort 78/133 (58.7%) 21/36 (58.3%) n.s.‡
Patients meeting Wingerchuk’s 2006
criteria
51/89 (57.3%) 16/27 (59.3%) n.s.‡
Brain stem involvement# n.s.‡
Total cohort 39/137 (28.5%) 7/38 (18.4%) n.s.‡
Patients meeting Wingerchuk’s 2006
criteria
31/137 (22.6%) 7/38 (18.4%) n.s.‡
†Considered “compatible with MS” by the reading radiologists in 11 cases (8.9%) in the seropositive group and in 3 cases (9.4%) in the seronegative group (p =
n.s.). #Clinical and/or MRI evidence. ‡Fisher’s exact test (2-tailed).
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Co-existing autoimmune disorders
Co-existing autoimmune disorders were present in 33/
165 (28.1%) patients; and in 46 additional cases, autoan-
tibodies (but not clinical signs) usually associated with
autoimmune disorders or indicating systemic autoimmu-
nity were reported (see legend to Table 3 for details).
Signs of co-existing autoimmunity were significantly
more frequent in the seropositive group (Table 3).
Other co-existing diseases
Seven patients (4%; all seropositive) had a history of
cancer, including breast cancer (3 cases), cervical cancer,
rectal carcinoma, anal carcinoma, vulvar carcinoma,
nasopharyngeal carcinoma, and skin cancer. Two addi-
tional patients were diagnosed with a monoclonal gam-
mopathy. Benign tumour diagnoses present in this
cohort included meningeoma (2 cases), fibroadenoma of
the breast, uterus myoma, and hepatic hemangiomas. In
three further patients hysterectomy and/or ovarectomy
for unspecified reasons had been performed. At least 21
patients had a history of severe and/or chronic infec-
tious diseases, including hepatitis C, hepatitis B, hepati-
tis A, tuberculosis, borreliosis, HPV (1 × condylomata
accuminata, 1 × verrucae planae), herpes zoster, herpes
labialis and herpes genitalis, meningitis, osteomyelitis,
pyelonephritis, salpingitis, and coxsackievirus infection.
Family history
In two seropositive cases, the patient’s father had report-
edly suffered from “multiple sclerosis”. A chronic
inflammatory CNS disease was also suspected in the
grandmother and in the brother, respectively, of two
further seropositive patients. Nine AQP4-positive
patients reported a family history of non-CNS autoim-
munity including rheumatoid arthritis (N = 7; including
the mother of the two patients with paternal MS), sys-
temic lupus erythematosus (SLE; 2), and diabetes melli-
tus (2). Some of these patients were diagnosed with co-
existing autoimmune disorders themselves (including
SLE, myasthenia gravis, autoimmune thyroiditis, and
arthritis).
Discussion
In this study we analysed the clinical and paraclincal
features associated with myelitis and optic neuritis in a
large cohort of Caucasian patients with neuromyelitis
optica spectrum disorders in a stratified fashion accord-
ing to the patients’ AQP4-Ab serostatus. Clinically, the
disease course was characterized by severe attacks in
many patients despite immunosuppressive and immuno-
modulatory treatment, often resulting in disability and
impaired mobility within short time. More than two
thirds of all myelitis attacks were associated with motor
symptoms (with sensorimotor paraparesis as the most
common single manifestation), and around half of all
motor attacks resulted in an MRC grade of 2 or lower
in one or more limbs. Every fourth motor attack was
associated with tetraparesis, leading to respiratory failure
in some cases, and in more than a quarter of patients,
the disease was not restricted to the spinal cord but
involved the brain stem as well. The rate of no or
incomplete recovery from myelitis was high (around
75%) already from the beginning, and worsened with the
number of subsequent relapses. Accordingly, around
40% of all patients with a history of myelitis had an
EDSS of 6 or higher at the end of the observational per-
iod. Similarly, the visual deficiency present during acute
ON attacks was often severe (visual acuity ≤ 0.1 in more
than 60% of all relapses), and remission was incomplete
in most cases. Motor symptoms at onset, tetraparesis
early in the disease course, and more than one myelitis
attack during the first disease year were identified as
possible predictors of a worse clinical outcome in
patients with long term follow-up. The median number
of relapses per year (0.53 myelitis attacks and 0.38 ON
attacks) was similar to that observed in patients with
MS under standard treatment with IFN-beta (0.29-1.82)
or glatiramer acetate (0.34-1.19)[42], but the time to
EDSS 6-6.5 (walking aid needed) was much shorter (7.8
years) than that noted even in untreated exacerbating-
remitting MS patients (23 years) [43]. The latter finding
is likely to reflect both the preferential affection of the
spinal cord in NMO as compared to MS and the differ-
ential modes of inflammatory tissue damage in the two
conditions. While MS primarily causes demyelination,
NMO attacks are often associated with severe necrosis
[44]. Seropositive and seronegative patients were found
to differ with regard to attack severity and clinical pre-
sentation. Visual acuity of ≤ 0.1 during acute ON attacks
was more frequent among seropositives, motor symp-
toms were more common in seropositive patients, the
median MRC grade during acute myelitis attacks worse,
and MRC grades ≤ 2 more frequent, in particular if
patients met Wingerchuk’s criteria [17]. On the other
hand, simultaneous myelitis and ON as well as bilateral
ON at disease onset, and sensory symptoms were more
frequent in the seronegative group. By contrast, the two
groups did not differ significantly with regard to the
median annualized total relapse rate, the median annual-
ized myelitis specific relapse rate, the median annualized
ON specific relapse rate, relapse outcome (no remission,
partial or complete remission), and the frequency of
brainstem involvement.
Given both the low remission rate (as compared to
MS) found in our study already at disease onset and the
fact that the first event was followed by a relapse after a
median latency of just 9 months (and only 5 months in
the seronegative group), early treatment and, therefore,
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an early diagnosis of NMO is crucial. However, this
study revealed a marked delay in the diagnosis of NMO
(16 months from onset if the disease started with myeli-
tis, and even 55 months if the disease started with ON;
p < 0.013). Most importantly, a substantial number of
patients (42.5%) were initially wrongly diagnosed with
MS, and 52.6% of these patients were treated at least
once with IFN-beta, a drug which is safe and effective in
MS but considered to be harmful in NMO [45-50]. In
addition to incorrect differential diagnostic considera-
tions on the part of treating physicians, other factors
may have also contributed to this delay. In some
patients the latency between the first ON attack and the
first myelitis attack or vice versa was extraordinarily
long. Also, the presence of supratentorial brain lesions,
which has only recently been recognized as a common
feature of NMO [36,51,52], as well as the fact that short
MRI lesions not exceeding two vertebral segments and/
or positive OCBs, a hallmark of MS, were present at
onset in some patients, might have played a role. The
median time to diagnosis was shorter among seronega-
tive patients (11 months) than among seropositive
patients (45 months), which is partly explained by the
fact that NMO started more frequently with simulta-
neous myelitis and ON in the seronegative group.
From a diagnostic point of view, the following findings
are of particular importance.
First, mild symptoms or a benign long-term course do
not rule out the diagnosis of NMO, but occur in a sub-
stantial number of (both seropositive and seronegative)
NMO cases. While the concept of benign MS is now
well recognized [53], only a few cases of benign NMO
have been reported thus far [54-56]. It is therefore of
interest that around 17% of patients with long-term fol-
low-up (≥ 100 months) in the present cohort were fully
ambulatory (EDSS < 4) at last examination, including
one (seropositive) case with an EDSS of 1.5 (indicating
minimal neurological signs, but no disability) after 102
months. Similarly, a considerable number of myelitis
attacks were either purely sensory (around 30%) or asso-
ciated with only mild paresis, especially in seronegatives.
Second, a subset of patients (irrespective of the AQP4-
Ab serostatus) may present with rare manifestations not
typically associated with NMO. While the broad major-
ity of patients presented with tetraparesis and parapar-
esis in our cohort, in a minority of cases hemiparesis,
Brown Sequard syndrome, or monoparesis may occur,
even at disease onset. NMO attacks may also exclusively
affect the brain stem, independent of myelitis or optic
neuritis, as observed in 15 cases in our series. Isolated
brain stem encephalitis may even be the presenting
symptom, as was the case in 5 of our patients. One of
these patients, a young girl, was initially falsely diag-
nosed with bulimia nervosa because of repeated
vomiting, others with gastro-intestinal infection. More-
over, besides intractable vomiting and hiccups, which
have been repeatedly described in NMO [23,57,58],
other brain stem symptoms such as dysphagia, laryngeal
spasm, and oculomotor dysfunction occurred in a subset
of patients and do not rule out the diagnosis of NMO as
demonstrated here. Accordingly, brainstem lesions as
detected by MRI were not in all cases restricted to the
medulla oblongata and to the diencephalon, which are
known sites of predilection in NMO [59], but may also
occur in the pons, the cerebral peduncles, and the cere-
bellar peduncles.
Third, most patients did not present with simulta-
neous myelitis and bilateral ON, the classical syndrome
described by Devic. Instead, NMO started in most cases
with unilateral ON and, more rarely, with isolated mye-
litis. Importantly, the first ON attack was followed by
myelitis after a median of just 14 months in the seropo-
sitive group, and the first myelitis was followed by ON
after a median of only 3 months. This corroborates find-
ings from previous, smaller studies, which found that
AQP4-Ab seropositivity in patients with isolated ON or
myelitis confers a high risk of conversion to NMO
within one year [18-21] and strongly underlines the
need for early prophylactic treatment in patients pre-
senting with seropositive isolated ON or myelitis.
We found a strong female preponderance in our
cohort. Interestingly, the female/male ratio was consid-
erably higher than that observed in MS (1:2) [60] in the
seropositive group (10.4), which is in accordance with a
smaller previous study [61], but was similar to MS in
the seronegative group (1.9). This finding further sup-
ports the concept that seropositive NMO is a distinct
entity, different from classical MS and seronegative
NMO. In line with the latter presumption, the median
age of onset (40 years) in the seropositive group was
higher by a decade than that in classical MS (29 years)
[60].
The mortality rate was much lower in the present
cohort (6% after a median observation time of 57.5
months) than that in a previously published North
American cohort, which reported a five-year survival
rate of only 68% [1]. This may partly reflect an increase
in awareness of the condition and thus earlier treatment.
While the median year of onset in our study was 2004
(range, 1977-2011), in that previous study disease had
started in 1985 in the relapsing subgroup, and in 1977
in the monophasic subgroup. The difference in mortality
rates might also be the result of improved treatment
options. Fifty-seven patients in our cohort were treated
with rituximab at least once over the course of disease,
and 37 with mitoxantrone, drugs that are now consid-
ered to be effective in NMO, but which were not avail-
able in the 1980s and 1990s when most of the patients
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reported by Wingerchuk and colleagues were seen.
Similarly, testing for NMO-IgG/AQP4-Ab, which largely
contributes to the laboratory differentiation of NMO
and classical MS and which can thus guide treatment
decisions, only became available in the middle of the
last decade. Finally, genetic factors might also play a
role. While around 40% of the patients in the North
American series were classified as ‘non-white’ by the
authors, our cohort consisted of an exclusively Cauca-
sian population. Importantly, only 5 of the 9 patients
who died during the observation period in our study
died from attack-related neurological complications.
Recent studies have revealed a high frequency of brain
lesions in Asian and mixed Asian/Caucasian NMO
cohorts. Our data corroborate this finding in an exclu-
sively Caucasian cohort. Supratentorial brain lesions
were detectable in around 50% of all patients at first
examination, irrespective of the AQP4-Ab antibody sta-
tus, both in the total cohort and among those patients
who met Wingerchuk’s criteria, and at least once over
the course of disease in 60.1%. The fact that around
17.7% of these MRIs were classified as “compatible with
MS” by the reading radiologists underscores the rele-
vance of AQP4-Ab, which was positive in 78.6% of these
patients, in the differential diagnosis of MS and NMO.
Besides AQP4-Ab, the length of the spinal cord
lesions is thought to discriminate between NMO and
MS with high specificity [36]. In fact, the first MRI
showed at least one longitudinally extensive lesion in
the vast majority of our patients. Importantly, however,
7.3% had a lesion shorter than three segments at first
examination. Such cases can pose a serious differential
diagnostic challenge (even more so as 60% had brain
lesions on their first MRI). In 8 of these patients, the
diagnosis of NMO could be established based on a posi-
tive AQP4-Ab test result. In the seronegative ones, the
diagnosis of NMO could only be made based on the
finding of lesions spanning over ≥ 3 segments on a fol-
low-up spinal MRI later in the disease course and a
negative brain MRI at onset. This underlines the impor-
tance of early AQP4-Ab testing also in patients present-
ing with myelitis and short spinal cord lesions as well as
a need for repeated spinal cord imaging in these
patients.
In the three largest previous studies [1,27,36], spinal
cord lesions were reported to have spanned over 3 or
more vertebral segments in most patients, but the exact
length was not stated. In our cohort, spinal lesions had
a median length of 6 segments, which is normally not
found in MS [36]. In addition, we evaluated whether
more than one spinal cord lesion were present, and if
so, calculated the total lesion load. In fact, 21 patients
had an additional second or even a third lesion already
at first examination, some of which also extended over
three or more segments, corresponding to a median
total lesion load of 8 vertebral segments. Again, such
high lesion load is very unusual in classical MS. In line
with the finding of more severe myelitis in the seroposi-
tive group, the total spinal cord lesion load was also
higher among the seropositives in our cohort, lesions >
= 6 segments were more frequent, and involvement of
the entire spinal cord was observed only among
seropositives.
At the time of first MRI examination, most patients
had lesions located both in the cervical and thoracic
portions of the spine. Among those with lesions
restricted to either of the two sites, cervical involvement
was slightly more common. However, 15 patients had
additional lesions of the lumbar portion and/or the
spinal conus. Together with our finding of multiple
lesions in a considerable subset of patients, these data
demonstrate that MRI examinations should not be
restricted to the cervical spine but should ideally include
the entire spinal cord.
The diagnosis of NMO according to Wingerchuk et al.
(2006) [36] could be made based on the presence of two
index events and brain and spinal cord MRI findings
alone in 79% of all NMO patients and in 74.4% of the
seropositive ones (not shown). Conversely, either brain
MRI or spinal cord MRI was not formally required in
25.6% of the AQP4-Ab positive NMO patients to estab-
lish the diagnosis. However, we do not recommend dis-
missing brain and spinal cord imaging in seropositive
cases, all the more as fulfilment of all three supportive
criteria has been demonstrated to improve the specificity
of the 2006 diagnostic criteria [36].
CSF findings in NMO are known to differ signifi-
cantly from those in classical MS [62-64]. In accor-
dance with previous studies, OCBs were present in
only one third of our patients (compared to > 95% in
MS) [65,66]. Importantly, more than half of patients
positive for OCBs at first LP became negative at fol-
low-up. This is in sharp contrast to MS, where OCBs
were shown to remain detectable over decades.
Accordingly, repeat LP performed during remission
may improve the CSF based laboratory differential
diagnosis of NMO and MS substantially. In a previous
study, we have shown that the polyspecific, intrathecal
humoral immune response to measles, rubella, and
varicella zoster (the so called ‘MRZ reaction’), a highly
sensitive (~90%) and possibly specific marker of classi-
cal MS, is mostly negative in NMO [39,40,63,67]. Cor-
roborating these findings, we found a negative MRZ
reaction in 11 additional patients in the present cohort.
It is of note that OCBs were rare and tended to disap-
pear over the course of disease also in seronegative
patients; also the MRZ reaction was negative in all five
seronegatives tested. This provides further support for
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the hypothesis that seronegative NMO is not simply a
clinical variant of MS.
Infections have been discussed in the past both as a
possible trigger of disease relapse in NMO and as a pos-
sible aetiological factor [1,68]. In our cohort, ON and
myelitis were reported to have been preceded by acute
infection at least once in 29.3% of the seropositive
patients and in 17.9% of the seronegative cases. This is
in good accordance with a study by Wingerchuk and
colleagues who found a frequency of 30% in a North
American mixed Caucasian/Asian cohort [1].
Both well defined co-existing autoimmune disorders as
well as serological signs of co-existing autoimmunity
were significantly more common in seropositive
patients. Besides lupus erythematosus, Sjögren’s syn-
drome, thyroid diseases, myasthenia gravis, or celiac dis-
ease, which have been all repeatedly observed in
association with NMO spectrum disorders [54,69-75], a
broad variety of other autoimmune conditions was pre-
sent in our patients, including pyoderma gangrenosum,
psoriasis, sarcoidosis, ankylosing spondylitis, collagenous
colitis, atopic dermatitis, rheumatoid arthritis, Sharp
syndrome, and vitiligo. The frequency of co-existing
autoimmunity found in our seropositive NMO patients
is higher than that observed in classical MS [76].
Four per cent of our patients had a history of cancer,
including breast cancer, cervical cancer, rectal cancer,
nasopharyngeal cancer, and skin cancer, all of whom
were positive for AQP4-Ab. This is of interest because
AQP4 was reported to be expressed in a variety of
tumour tissues [77]. However, so far it is unknown
whether seropositive NMO may occur as a paraneoplas-
tic disorder, or whether the co-occurrence of the two
conditions is a simple coincidence. Interestingly, our
findings are in exact accordance with a recent North
American study that had reported a frequency of cancer
in NMO spectrum disorders in 5% [78]. In three addi-
tional patients, hysterectomy and/or ovarectomy was
performed, though it remained unclear from the
patients’ records whether a tumour was present.
We recognize that there are some obvious limitations
of our study. First, the study design was retrospective, as
in all previous studies, and a multitude of neurological
centres was involved. However, due to the low preva-
lence of NMO in Caucasians, prospective monocentre
studies including sufficiently large patient numbers are
impracticable. Moreover, the multicentre design of this
study, which included more than 25 academic centres,
reduces the risk of referral bias, which was acknowl-
edged as a possible limitation by the authors of the two
largest previous monocentre studies [1,36]. Second,
similar to previous studies, analysis of MRI results was
based upon patient records. However, this disadvantage
is partly compensated for by the very high number of
brain (N = 326) and spinal cord (N = 326) MRI results
available for analysis. Third, as in previous studies, most
patients were treated at least once with immunomodula-
tory or immunosuppressive agents. However, given the
much more aggressive course of disease in NMO com-
pared to MS, which requires early treatment, a longitu-
dinal study on untreated patients with NMO cannot be
performed. Moreover, AQP4-Ab has been previously
shown to remain detectable in NMOSD even with
strong immunosuppression. In a recent study, we found
AQP4-Ab in 95/96 samples obtained from patients trea-
ted with a broad variety of immunosuppressive or
immunomodulatory drugs such as azathioprine, rituxi-
mab, cyclophosphamide, IVIG, interferon beta, glatira-
mer acetate, steroids, or mitoxantrone [8]. Therefore, we
do not believe that treatment effects played an impor-
tant role in the present study with regard to stratifica-
tion, though we can, of course, not completely exclude
such effects. Fourth, assay sensitivity could be a poten-
tial limitation. However, 98.3% of our patients were
tested using recombinant assays. Recombinant assays
employing human AQP4-Ab have been repeatedly
shown in independent studies to be significantly more
sensitive compared to indirect immunofluorescence on
rodent brain tissue [4,5,38,79], which was used in many
of the previous studies. 19/19 (100%) samples from the
seronegative group had remained negative at repeat test-
ing (up to three times) or when tested in another assay
(up to four methods); from the remaining patients no
data on repeat testing and no samples were available
due to the retrospective setting of this study. Fifth,
patients with a benign long-term course are less likely
to be admitted to hospital and might thus be under-
represented in the present cohort. However, this type of
potential bias is inherent in hospital-based studies and
cannot be completely avoided. It is important in this
context that all centres involved in the present study
also have specialized neuroinflammatory outpatient
departments and that patients were recruited among
both inpatients and outpatients. Finally, the threshold
for admission is low in Germany, where public health-
care is free. Accordingly, 7.4% of our patients had an
EDSS of 0-1.5, i.e. no disability, at first admission.
In summary, our study provides a comprehensive
overview of the clinical, MRI, and laboratory features of
NMO in Caucasians and extends our knowledge of the
clinical, diagnostic and prognostic impact of AQP4 anti-
body positive serostatus in this rare yet often devastating
condition.
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